Nureca Limited
NSE: NURECAMedical Equipment & SuppliesTrade-to-trade true
Share price
₹331.65
+0.09% close of 9 Oct 2026
Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.
Business score
How strong the business is, in one number. The parts behind it are in Pro.
52
out of 100 · worked out 9 Oct 2026
Your ratios
The numbers you want to see first. Tap Edit to change them.
Market cap
₹332 Cr
P/E ratio
66.3
P/B ratio
1.8
ROCE
3.3%
ROE
1.1%
Dividend yield
0.0%
Price & valuation chart
How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.
Answers
Simple answers to the questions investors ask most, from the company's own numbers.
How fast it has been growing
Our sales figures for this company step up at Sep 2020 and we hold nothing that says why, so we cannot honestly quote a growth rate across it.
Whether it grew faster than its sector
Our sales figures for this company step up at Sep 2020 and we hold nothing that says why, so there is no honest growth rate of its own to set against its sector.
Room to re-rate, or risk of de-rating
Too little price history yet to compare it with its own past.
Whether growth justifies the valuation
Priced at 2.2 times its growth rate, on earnings growth of 30%.
| Profit growth | Price per ₹1 profit | Per 1% growth | |
|---|---|---|---|
| Nureca Limited — this one | 30%/yr | 66.3× | ₹2.2 |
| Molbio Diagnostics Limited | — | 99.3× | — |
| Poly Medicure Limited | 15%/yr | 50.6× | ₹3.4 |
| Fischer Medical Ventures Limited | 831%/yr | 80.6× | — |
| Tarsons Products Limited | — | 147.1× | — |
| Laxmi Dental Limited | 124%/yr | 31.0× | — |
Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
How it compares with its peers
Against companies the exchange files under the same label (Medical Equipment & Supplies), it ranks 8 of 8 on returns, 6 of 6 on growth, 8 of 8 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
What makes it hard to beat — and is that still true?
No durable advantage shows in the numbers: it earns 3.3% on capital, ahead of 0% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Whether its growth pays for itself
No — Over the last five years the business itself consumed ₹8 crore of cash before any plant spend. But only about 20 of every 100 rupees of profit it reported over 8 years arrived as cash — the rest is tied up. Its cash comes back more slowly than it used to: it went from being waiting 109 days for its cash to waiting 145 days for its cash.
Profit reality check
Is the profit real cash? Simple checks on the accounts. Facts only, not advice.
6 of 10 checks clear · 60%
Latest result
What the last results showed. Whether management kept its word is in Pro.
Results are expected soon.
Checklist before you investPRO
Points for and against, in one list.
Key numbers & peers
The main numbers grouped by topic, and how the company compares with similar ones.
Price
- Market cap
- ₹332 Cr
- Prev close
- ₹331.65
- 52w High
- ₹376
- 52w Low
- ₹204
- Enterprise value
- ₹292 Cr
- Beta
- 0.9
- Price CAGR 1y
- 43.0%
- Price CAGR 3y
- -2.0%
- Price CAGR 5y
- -31.0%
- Price CAGR 10y
- —
Ratios
- Return on assets
- 1.0%
- PEG ratio
- 2.4
- P/E ratio
- 66.3
- P/B ratio
- 1.8
- EV / EBITDA
- 70.1
- Industry P/E
- 58.3
- ROCE
- 3.3%
- ROCE 5y average
- 5.4%
- ROE
- 1.1%
- Debt / Equity
- 0.0
- Interest coverage
- 6.0
- Dividend yield
- 0.0%
- ROE 3y average
- -1.0%
- ROE last year
- 1.0%
Annual P&L
- Annual revenue
- ₹147 Cr
- Annual profit
- ₹2 Cr
- Operating margin
- 0.1%
- Net profit margin
- 1.4%
- EBITDA margin
- 0.0%
- Sales growth 3y
- 9.8%
- Sales growth 5y
- -7.1%
- Profit growth 3y
- 30.0%
- Profit growth 5y
- -46.0%
- EPS
- ₹2.2
- Sales growth TTM
- 24.0%
- Profit growth TTM
- 176.0%
- Dividend payout
- 0.0%
Quarter P&L
- Sales latest quarter
- ₹40 Cr
- Profit latest quarter
- ₹3 Cr
- YoY quarterly sales growth
- 18.0%
- YoY quarterly profit growth
- 279.0%
- OPM latest quarter
- 8.5%
Balance Sheet
- Book Value
- ₹181
- Face Value
- ₹10.0
- Total debt
- ₹2 Cr
- Total cash
- ₹41 Cr
- Borrowings
- ₹2 Cr
- Reserves / Equity
- 17.1
Cash Flow
- Operating cash flow
- ₹3 Cr
- Free cash flow
- -₹3 Cr
- FCF yield
- -1.3%
- Net cash flow
- -₹2 Cr
Shareholding
- Promoter holding
- 68.1%
- FII holding
- 0.1%
- DII holding
- 0.2%
- Public holding
- 31.6%
Peer comparison
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield % | Profit qtr ₹ Cr | Profit var % | Sales qtr ₹ Cr | Sales var % | ROCE % |
|---|---|---|---|---|---|---|---|---|---|
| Molbio Diagnosti | 1,511.60 | 80.2 | 17,420 | 0.00 | 56.6 | 522.3 | 399.4 | 319.0 | 18.0 |
| Poly Medicure | 1,604.70 | 50.8 | 16,265 | 0.22 | 85.3 | -7.6 | 525.4 | 30.3 | 12.5 |
| Fischer Medical | 31.72 | 90.5 | 2,216 | 0.15 | 3.8 | -22.0 | 81.9 | 249.5 | 11.4 |
| Tarsons Products | 334.45 | 150.3 | 1,780 | 0.00 | -1.4 | -180.9 | 110.2 | 20.7 | 4.6 |
| Q-Line Biotech | 662.00 | 27.3 | 1,544 | 0.00 | 34.4 | 147.3 | 197.9 | -8.6 | 22.4 |
| Laxmi Dental | 191.65 | 30.3 | 1,055 | 0.00 | 10.3 | 22.8 | 74.7 | 13.9 | 15.1 |
| Hemant Surgical | 631.95 | 54.3 | 919 | 0.00 | 12.8 | 159.2 | 166.7 | 189.2 | 18.9 |
| Nureca | 342.80 | 75.4 | 327 | 0.00 | 3.1 | 279.0 | 40.3 | 18.0 | 3.3 |
| Median | 334.45 | 36.3 | 667 | 0.00 | 4.2 | 19.8 | 74.7 | 21.5 | 15.1 |
Competes with: Fischer Medical Ventures Limited, Laxmi Dental Limited, Molbio Diagnostics Limited, Poly Medicure Limited, Tarsons Products Limited
Quarterly results
Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.
| Line item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 31 | 22 | 17 | 20 | 31 | 26 | 32 | 34 | 38 | 40 | 35 | 40 |
| Expenses | 24 | 30 | 27 | 21 | 23 | 34 | 30 | 31 | 35 | 34 | 36 | 41 | 37 |
| Material Cost | 3.86 | 4.08 | 5.76 | 10 | 8.16 | 4.96 | |||||||
| Change in Inventories | -10 | -0.83 | 1.03 | -9.96 | 0.90 | 6.21 | |||||||
| Purchases of Stock-in-Trade | 25 | 19 | 17 | 25 | 12 | 14 | |||||||
| Employee Cost | 4.27 | 4.45 | 4.17 | 4.32 | 4.10 | 4.43 | |||||||
| Other Expenses | 7.30 | 8.11 | 6.49 | 6.83 | 16 | 7.80 | |||||||
| Operating Profit | -2.90 | 1.38 | -4.25 | -4.43 | -2.36 | -2.35 | -4.01 | 1.20 | -0.56 | 3.27 | 3.25 | -5.78 | 3.42 |
| OPM % | -14 | 4.40 | -19 | -26 | -12 | -7.53 | -15 | 3.78 | -1.64 | 8.66 | 8.20 | -16 | 8.48 |
| Other Income | 2.67 | 3.20 | 5.90 | -1.26 | 5.79 | 3.17 | 1.48 | 1.99 | 2.57 | 2.32 | 2.19 | 1.02 | 1.82 |
| Exceptional items (within Other Income) | 0 | 0 | 0 | 0 | 0 | 0 | |||||||
| Interest | 0.12 | 0.08 | 0.11 | 0.18 | 0.15 | 0.27 | 0.18 | 0.62 | 0.25 | 0.46 | 0.28 | 0.30 | 0.20 |
| Depreciation | 0.58 | 0.59 | 0.59 | 0.60 | 0.66 | 0.62 | 0.54 | 0.52 | 0.53 | 0.54 | 0.50 | 0.45 | 0.61 |
| Profit before tax | -0.93 | 3.91 | 0.95 | -6.47 | 2.62 | -0.07 | -3.25 | 2.05 | 1.23 | 4.59 | 4.66 | -5.51 | 4.43 |
| Tax % | -24 | 26 | 82 | -36 | 37 | 586 | -14 | -20 | 34 | 21 | 20 | 11 | 31 |
| Net Profit | -0.71 | 2.89 | 0.17 | -4.15 | 1.66 | -0.48 | -2.80 | 2.47 | 0.81 | 3.63 | 3.73 | -6.09 | 3.07 |
| EPS in Rs | -0.71 | 2.89 | 0.17 | -4.15 | 1.66 | -0.48 | -2.80 | 2.47 | 0.81 | 3.63 | 3.91 | -6.38 | 3.22 |
| Diluted EPS in Rs | 2.47 | 0.81 | 3.63 | 3.91 | -6.45 | 3.21 |
Profit & loss
Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 62 | 99 | 213 | 256 | 111 | 92 | 110 | 147 | 153 |
| Expenses | 53 | 90 | 152 | 200 | 126 | 102 | 117 | 147 | 149 |
| Material Cost | 11 | 28 | |||||||
| Change in Inventories | -6.96 | -8.86 | |||||||
| Purchases of Stock-in-Trade | 64 | 73 | |||||||
| Employee Cost | 15 | 17 | |||||||
| Other Expenses | 34 | 37 | |||||||
| Operating Profit | 9 | 10 | 62 | 56 | -15 | -10 | -8 | 0 | 4 |
| OPM % | 15 | 10 | 29 | 22 | -13 | -11 | -7 | 0.10 | 2.70 |
| Other Income | 0 | 0 | 3 | 8 | 7 | 11 | 12 | 8 | 7 |
| Exceptional items (within Other Income) | 0 | 0 | |||||||
| Interest | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1.28 | 1 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2.34 | 2.02 | 2 |
| Profit before tax | 9 | 9 | 62 | 61 | -11 | -3 | 1.34 | 4.98 | 8 |
| Tax % | 30 | 26 | 26 | 26 | -23 | -30 | 37 | 58 | |
| Net Profit | 6 | 6 | 46 | 45 | -8 | -2 | 0.85 | 2.08 | 4 |
| EPS in Rs | 6,230 | 6,400 | 46 | 45 | -8.25 | -1.79 | 0.85 | 2.18 | 4.38 |
| Diluted EPS in Rs | 0.85 | 2.11 | |||||||
| Dividend Payout % | 0 | 0 | 4 | 7 | 0 | 0 | 0 | 0 |
Compounded growth
Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.
Compounded sales growth
- 10 years
- —
- 5 years
- -7%
- 3 years
- 10%
- TTM
- 24%
Compounded profit growth
- 10 years
- —
- 5 years
- -46%
- 3 years
- 30%
- TTM
- 176%
Stock price CAGR
- 10 years
- —
- 5 years
- -31%
- 3 years
- -2%
- 1 year
- 43%
Return on equity
- 10 years
- —
- 5 years
- 3%
- 3 years
- -1%
- Last year
- 1%
Balance sheet
What the company owns and what it owes, at the end of each year. ₹ crore.
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 9.54 |
| Reserves | 8 | 15 | 153 | 193 | 185 | 183 | 184 | 171 |
| Borrowings | 0 | 10 | 4 | 4 | 3 | 3 | 5 | 2 |
| Other Liabilities | 15 | 9 | 19 | 12 | 8 | 10 | 11 | 13 |
| Minority Interest | 0 | 0 | ||||||
| Total Liabilities | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 196 |
| Fixed Assets | 1 | 1 | 4 | 10 | 9 | 7 | 9 | 14 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 33 | 59 | 94 | 1 | 1 |
| Other Assets | 23 | 33 | 182 | 175 | 139 | 104 | 200 | 182 |
| Total Assets | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 196 |
Cash flows
Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | -8 | 35 | 1 | 10 | -3 | -19 | 3.30 |
| Cash from Investing Activity | -0 | -0 | -110 | -3 | -16 | 18 | 8 | 14 |
| Cash from Financing Activity | -0 | 8 | 92 | -7 | -2 | -1 | -0 | -20 |
| Net Cash Flow | 0 | -0 | 17 | -9 | -8 | 14 | -11 | -2 |
| Free Cash Flow | 0 | -8 | 34 | -5 | 10 | -4 | -23 | -3.41 |
Ratios
How fast customers pay, how long stock sits, and how well capital earns — year by year.
| Line item | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 47 | 6 | 4 | 14 | 6 | 11 | 19 |
| Inventory Days | 123 | 93 | 135 | 174 | 167 | 186 | 214 | 187 |
| Days Payable | 89 | 33 | 32 | 13 | 24 | 31 | 35 | 20 |
| Cash Conversion Cycle | 87 | 107 | 109 | 165 | 157 | 161 | 190 | 186 |
| Working Capital Days | 45 | 85 | 61 | 109 | 156 | 176 | 163 | 145 |
| ROCE % | 57 | 67 | 33 | -6 | -4 | 1 | 3 |
Price trend
The price as a Renko brick chart: small moves drop out so the bigger path stands out.
Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.
Open interestPRO
Where option traders are positioned on this stock.
Industry numbers
The numbers that matter most in this industry, from the company's own filings.
1 when an audit qualification is filed as repetitive
0.00flag
2026-03-31
the company's own unlisted debt securities in default at period end
0.00cr
2026-06-30
the company's own loans / revolving facilities in default at period end (standalone filing)
0.00cr
2026-06-30
net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash
-40.01inr_cr
2026-03-31
guarantees / comfort given for promoter, promoter group, directors and KMP
0.00cr
2026-03-31
loans outstanding to promoter, promoter group, directors and KMP (governance filing)
0.00cr
2026-03-31
security given for the borrowing of promoter, promoter group, directors and KMP
0.00cr
2026-03-31
News
News and filings about Nureca Limited. Open one to see why it matters.
No recent news for this company.
Supply chain
Who it buys from, sells to and competes with — as recorded in our map of company links.
Competes with
Uses as raw material
- components and sub-assemblies for home-healthcare device manufacturing (BP monitors, nebulizers, electric massagers, oral and infrared thermometers, heating pads, breast pumps, vaporizers, stethoscopes)
- finished home-healthcare and wellness devices bought as stock-in-trade from third-party manufacturers
- orthopedic cushions, supports and soft orthopedic goods inputs
Sells to
- Amazon Seller Services India · Dr Trust / Dr Physio devices via online marketplace. FY26 AR p.4 names amazon in the e-com…
- ETERNAL LIMITED · Dr Trust / Dr Physio home-healthcare and wellness devices sold through the Blinkit quick-c…
- Swiggy Limited · Dr Trust home-healthcare devices (digital weighing scales, body fat analyzers, BP monitors…
- Tata 1mg (Tata 1mg Technologies) · Dr Trust devices via the TATA 1mg online pharmacy/healthcare marketplace - named in FY26 A…
- Zepto · Dr Trust devices on the Zepto quick-commerce platform (company release Apr-2025: 'already…
About
What the company is, from our own records: where it sits, where it makes things, and what it is made of.
- Sector
- Healthcare
- Industry
- Medical Equipment & Supplies
- Classification
- Healthcare › Medical Equipment & Supplies
- ISIN
- INE0DSF01015
Plants
- Nureca Technologies Private Limited - Mohali medical device plant
News impact
Big market events that reach Nureca Limited, and how the effect spreads.
28 Jun, 14:22 IST · Market event · medium impact
Health ministry proposes amendments to Medical Devices Rules
Who it hits first
- Domestic medical-device manufacturers face simpler and faster licensing under the proposed Medical Devices Rules amendments; lower compliance cost and quicker product approvals primarily benefit pure-play domestic makers (POLYMED, LAXMIDENTL).
Who may gain
- Poly Medicure (POLYMED) — largest listed pure-play domestic device maker
- Laxmi Dental (LAXMIDENTL) — domestic dental-device maker
Along the supply chain
Downstream
Hospitals, diagnostic chains and distributors that buy domestic devices may get faster product availability and modestly better pricing as licensing friction falls.
Upstream
Upstream component/raw-material suppliers (medical-grade polymers, electronics) see no direct change — the benefit is regulatory (licensing friction), not input-sourcing driven.
Where demand moves
Business
Eased licensing lowers entry/expansion friction for domestic device makers (POLYMED, LAXMIDENTL), supporting import substitution in an ~82%-import-dependent market; import-led players (NURECA) face an ambiguous net effect since registration may also speed up.
Capital
Marginal positive sentiment toward listed domestic device makers; the draft (non-final) status is too soft to drive sector rotation, so capital impact is limited to stock-specific re-rating if the final rule confirms the easing.
How it spreads across sectors
Healthcare
Marginal positive for device-using hospitals and diagnostic chains via faster device availability
Medical Devices
Lower regulatory friction → margin/throughput tailwind for domestic device makers
When it plays out
Immediate
Muted price reaction expected — this is a draft notification, not a final rule (historical precedent: POLYMED 1d +0.85% / -0.90% on 2023 policy events).
Medium term
If finalized, lower compliance cost and faster approvals reinforce the domestic-manufacturing tailwind (POLYMED renal +35% YoY in FY24 after Oct-23 device rules); 1-6 month positive for POLYMED and LAXMIDENTL.
Short term
Watch for consultation feedback and the final notification; domestic device-maker sentiment modestly positive.
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividends
| 24 Feb 2022 | interim | ₹3 |
|---|---|---|
| 21 Sep 2021 | unspecified | ₹2 |
Splits, bonuses & buybacks
- daily-prices repair: 8 rows from NSE's archive (replace 2, delete 1, insert 5), 2023-11-12..2026-02-01 (docs/flat_day_repair.md)1× · 12 Nov 2023
Insider trades
| Disclosed | Who | Type | Shares | Value ₹ Cr |
|---|---|---|---|---|
| 1 Oct 2026 | Saurabh Goyal · Promoter | BUY | 11,368 | 0.42 |
| 30 Sep 2026 | Saurabh Goyal · Promoter | BUY | 3,100 | 0.11 |
| 29 Sep 2026 | Saurabh Goyal · Promoter | BUY | 5,618 | 0.20 |
| 28 Sep 2026 | Saurabh Goyal · Promoter | BUY | 5,614 | 0.19 |
| 26 Sep 2026 | Saurabh Goyal · Promoter | BUY | 2,430 | 0.08 |
| 26 Sep 2026 | Saurabh Goyal · Promoter | BUY | 216 | 0.01 |
| 25 Sep 2026 | Saurabh Goyal · Promoter | BUY | 19,380 | 0.67 |
| 25 Sep 2026 | Saurabh Goyal · Promoter | BUY | 5,569 | 0.19 |
| 25 Sep 2026 | Saurabh Goyal · Promoter | BUY | 761 | 0.03 |
| 25 Sep 2026 | Saurabh Goyal · Promoter | BUY | 746 | 0.03 |
Documents
Annual reports, results presentations and earnings calls, straight from the source.
- Annual report · 2025-263 Jul 2026
- Results presentation30 Jun 2026
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.